Long‐term efficacy and safety of a hyaluronic acid dermal filler based on Tri‐Hyal technology on restoration of midface volume

Abstract

AbstractIntroductionArt Filler Volume (AFV) is a hyaluronic acid (HA)‐based filler formulated with “Tri‐Hyal” technology, a unique combination of three sizes of HA chains. This study assessed AFV efficacy and safety over 18 months when used to restore midface volume.MethodsDuring this open‐label study, a maximum of 1.8 mL AFV was injected into each cheek area on Day 0 (D0). Subjects were evaluated at D21, when, if necessary, a retouch could be performed (maximum 1.2 mL per cheek). Subjects were evaluated at seven follow‐up visits through to D540. The primary assessment was based on the evolution of the Medicis Midface Volume Scale (MMVS) grade on D21. Secondary outcomes were local and general adverse events, investigator‐ and subject‐assessed Global Aesthetic Improvement Scale scores and changes in self‐esteem.ResultsOf the 79 healthy Caucasians enrolled (mean age 54.8 years), 25 required a second injection. In the intention‐to‐treat population, mean overall MMVS scores improved significantly from D0 (3.2 ± 0.4) to D21 (1.8 ± 0.6) and D42 (1.7 ± 0.6) (all p < 0.0001). MMVS scores for each cheek also improved significantly, irrespective of retouch on D21: 22% of injections showed a persistent benefit at D540 without retouch. The most common adverse events were pain on palpation (19%), erythema (15%) and edema (13%); most were mild or moderate and resolved within 2 weeks.ConclusionAFV produces a sustained objective and subjective midface volume restoration in female and male subjects, often without retouching, and was well tolerated.